{"pmid":32281877,"title":"COVID-19 Lung Injury is Not High Altitude Pulmonary Edema.","text":["COVID-19 Lung Injury is Not High Altitude Pulmonary Edema.","Not applicable.","High Alt Med Biol","Luks, Andrew","Freer, Luanne","Grissom, Colin","McIntosh, Scott E","Schoene, Robert B","Swenson, Erik","Hackett, Peter H","32281877"],"abstract":["Not applicable."],"journal":"High Alt Med Biol","authors":["Luks, Andrew","Freer, Luanne","Grissom, Colin","McIntosh, Scott E","Schoene, Robert B","Swenson, Erik","Hackett, Peter H"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32281877","week":"202016|Apr 13 - Apr 19","doi":"10.1089/ham.2020.0055","source":"PubMed","topics":["Mechanism","Treatment"],"weight":1,"_version_":1663989232636526593,"score":7.979339,"similar":[{"pmid":32275925,"title":"Clinical and Imaging features of COVID-19 Patients: Analysis of Data from High-Altitude Areas.","text":["Clinical and Imaging features of COVID-19 Patients: Analysis of Data from High-Altitude Areas.","J Infect","Zeng, Jie","Peng, Shengkun","Lei, Yu","Huang, Jianxin","Guo, Yang","Zhang, Xiaoqin","Huang, Xiaobo","Pu, Hong","Pan, Lingai","32275925"],"journal":"J Infect","authors":["Zeng, Jie","Peng, Shengkun","Lei, Yu","Huang, Jianxin","Guo, Yang","Zhang, Xiaoqin","Huang, Xiaobo","Pu, Hong","Pan, Lingai"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32275925","week":"202015|Apr 06 - Apr 12","doi":"10.1016/j.jinf.2020.03.026","source":"PubMed","topics":["Diagnosis"],"weight":1,"_version_":1663712077909327875,"score":60.4101},{"pmid":32034638,"title":"Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury.","text":["Compensation of ACE2 Function for Possible Clinical Management of 2019-nCoV-Induced Acute Lung Injury.","Virol Sin","Wu, Yuntao","32034638"],"journal":"Virol Sin","authors":["Wu, Yuntao"],"date":"2020-02-09T11:00:00Z","year":2020,"_id":"32034638","week":"20206|Feb 03 - Feb 09","doi":"10.1007/s12250-020-00205-6","source":"PubMed","topics":["Mechanism"],"weight":1,"_version_":1663352134721077248,"score":55.090157},{"pmid":32274341,"pmcid":"PMC7132021","title":"Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease.","text":["Characteristics and Mechanism of Liver Injury in 2019 Coronavirus Disease.","An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (2019 coronavirus disease, COVID-19) since December 2019, from Wuhan, China, has been posing a significant threat to global human health. The clinical features and outcomes of Chinese patients with COVID-19 have been widely reported. Increasing evidence has witnessed the frequent incident liver injury in COVID-19 patients, and it is often manifested as transient elevation of serum aminotransferases; however, the patients seldom have liver failure and obvious intrahepatic cholestasis, unless pre-existing advanced liver disease was present. The underlying mechanisms of liver injury in cases of COVID-19 might include psychological stress, systemic inflammation response, drug toxicity, and progression of pre-existing liver diseases. However, there is insufficient evidence for SARS-CoV-2 infected hepatocytes or virus-related liver injury in COVID-19 at present. The clinical, pathological and laboratory characteristics as well as underlying pathophysiology and etiology of liver injury in COVID-19 remain largely unclear. In this review, we highlight these important issues based on the recent developments in the field, for optimizing the management and treatment of liver injury in Chinese patients with COVID-19.","J Clin Transl Hepatol","Li, Jie","Fan, Jian-Gao","32274341"],"abstract":["An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (2019 coronavirus disease, COVID-19) since December 2019, from Wuhan, China, has been posing a significant threat to global human health. The clinical features and outcomes of Chinese patients with COVID-19 have been widely reported. Increasing evidence has witnessed the frequent incident liver injury in COVID-19 patients, and it is often manifested as transient elevation of serum aminotransferases; however, the patients seldom have liver failure and obvious intrahepatic cholestasis, unless pre-existing advanced liver disease was present. The underlying mechanisms of liver injury in cases of COVID-19 might include psychological stress, systemic inflammation response, drug toxicity, and progression of pre-existing liver diseases. However, there is insufficient evidence for SARS-CoV-2 infected hepatocytes or virus-related liver injury in COVID-19 at present. The clinical, pathological and laboratory characteristics as well as underlying pathophysiology and etiology of liver injury in COVID-19 remain largely unclear. In this review, we highlight these important issues based on the recent developments in the field, for optimizing the management and treatment of liver injury in Chinese patients with COVID-19."],"journal":"J Clin Transl Hepatol","authors":["Li, Jie","Fan, Jian-Gao"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32274341","week":"202015|Apr 06 - Apr 12","doi":"10.14218/JCTH.2020.00019","keywords":["COVID-19","Clinical characteristics","Liver injury","Mechanism","SARS-CoV-2"],"source":"PubMed","locations":["Wuhan","China","Chinese","Chinese"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis","Mechanism"],"weight":1,"_version_":1663712077831733248,"score":52.833435},{"pmid":32174095,"title":"[Advances in the research of mechanism of pulmonary fibrosis induced by Corona Virus Disease 2019 and the corresponding therapeutic measures].","text":["[Advances in the research of mechanism of pulmonary fibrosis induced by Corona Virus Disease 2019 and the corresponding therapeutic measures].","The Corona Virus Disease 2019 (COVID-19) outbroke in Wuhan, China in December 2019 and the severe acute respiratory syndrome (SARS) outbroke in Guangzhou, China in 2003 were caused by highly pathogenic coronaviruses with high homology. Since the 2019 novel coronavirus has strong transmissibility and progress rapidly. It has caused negative social effects and massive economic damage on a global scale. While there is currently no vaccine or effective drugs. Pulmonary fibrosis is a pulmonary disease with progressive fibrosis, which is the main factor leading to pulmonary dysfunction and quality of life decline in SARS survivors after recovery. Extensive epidemiological, viral immunological, and current clinical evidences support the possibility that pulmonary fibrosis may be one of the major complications in COVID-19 patients. Although there are no reports on the mechanism of COVID-19 inducing pulmonary fibrosis, based on the existing theoretical basis, we focus on the possible mechanism of COVID-19 sustained lung damaging, the key role of abnormal immune mechanism in the initiation and promotion of pulmonary fibrosis, and the corresponding therapeutic measures.","Zhonghua Shao Shang Za Zhi","Wang, J","Wang, B J","Yang, J C","Wang, M Y","Chen, C","Luo, G X","He, W F","32174095"],"abstract":["The Corona Virus Disease 2019 (COVID-19) outbroke in Wuhan, China in December 2019 and the severe acute respiratory syndrome (SARS) outbroke in Guangzhou, China in 2003 were caused by highly pathogenic coronaviruses with high homology. Since the 2019 novel coronavirus has strong transmissibility and progress rapidly. It has caused negative social effects and massive economic damage on a global scale. While there is currently no vaccine or effective drugs. Pulmonary fibrosis is a pulmonary disease with progressive fibrosis, which is the main factor leading to pulmonary dysfunction and quality of life decline in SARS survivors after recovery. Extensive epidemiological, viral immunological, and current clinical evidences support the possibility that pulmonary fibrosis may be one of the major complications in COVID-19 patients. Although there are no reports on the mechanism of COVID-19 inducing pulmonary fibrosis, based on the existing theoretical basis, we focus on the possible mechanism of COVID-19 sustained lung damaging, the key role of abnormal immune mechanism in the initiation and promotion of pulmonary fibrosis, and the corresponding therapeutic measures."],"journal":"Zhonghua Shao Shang Za Zhi","authors":["Wang, J","Wang, B J","Yang, J C","Wang, M Y","Chen, C","Luo, G X","He, W F"],"date":"2020-03-17T11:00:00Z","year":2020,"_id":"32174095","week":"202012|Mar 16 - Mar 22","doi":"10.3760/cma.j.cn501120-20200307-00132","keywords":["Acute respiratory distress syndrome","Corona Virus Disease 2019","Cytokines","Immune system","Pulmonary fibrosis"],"source":"PubMed","locations":["Guangzhou","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352133905285120,"score":52.8155},{"pmid":32274570,"title":"COVID-19 in the heart and the lungs: could we \"Notch\" the inflammatory storm?","text":["COVID-19 in the heart and the lungs: could we \"Notch\" the inflammatory storm?","From January 2020, coronavirus disease (COVID-19) originated in China has spread around the world. The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The presence of myocarditis, cardiac arrest, and acute heart failure in COVID-19 patients suggests the existence of a relationship between SARS-CoV-2 infection and cardiac disease. The Notch signalling is a major regulator of cardiovascular function and it is also implicated in several biological processes mediating viral infections. In this report we discuss the possibility to target Notch signalling to prevent SARS-CoV-2 infection and interfere with the progression of COVID-19- associated heart and lungs disease.","Basic Res Cardiol","Rizzo, Paola","Vieceli Dalla Sega, Francesco","Fortini, Francesca","Marracino, Luisa","Rapezzi, Claudio","Ferrari, Roberto","32274570"],"abstract":["From January 2020, coronavirus disease (COVID-19) originated in China has spread around the world. The disease is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The presence of myocarditis, cardiac arrest, and acute heart failure in COVID-19 patients suggests the existence of a relationship between SARS-CoV-2 infection and cardiac disease. The Notch signalling is a major regulator of cardiovascular function and it is also implicated in several biological processes mediating viral infections. In this report we discuss the possibility to target Notch signalling to prevent SARS-CoV-2 infection and interfere with the progression of COVID-19- associated heart and lungs disease."],"journal":"Basic Res Cardiol","authors":["Rizzo, Paola","Vieceli Dalla Sega, Francesco","Fortini, Francesca","Marracino, Luisa","Rapezzi, Claudio","Ferrari, Roberto"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32274570","week":"202015|Apr 06 - Apr 12","doi":"10.1007/s00395-020-0791-5","keywords":["ADAM17","Angiotensin-converting enzyme 2","COVID-19","Cardiovascular disease","Coronavirus disease","Furin","Notch"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663712077829636097,"score":51.80307}]}